ArticleDiscover oncology2026
miR-4787-3p and miR-581 as predictive biomarkers for fibrosis and prognosis in pancreatic cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundPancreatic cancer (PC) is characterized by a profoundly immunosuppressive and fibrotic tumor microenvironment, driven largely by cancer-associated fibroblasts (CAFs). While microRNAs (miRNAs) are key regulators in PC, their specific roles in stromal fibrosis remain poorly understood. This study aims to investigate the prognostic and fibrotic relevance of miR-4787-3p and miR-581 in PC.
methodsWe identified differentially expressed miRNAs from The Cancer Genome Atlas (TCGA) database. MiR-4787-3p and miR-581 were selected for their prognostic value using Cox regression and Kaplan-Meier analysis. Their expression was validated in vitro using a co-culture model of PC cells and CAFs, and in clinical blood and tissue samples via RT-PCR, with correlations to clinical-pathological features and fibrosis markers (TGF-β1, COL1A1) assessed.
resultsTCGA analysis revealed significant downregulation of both miRNAs in PC tissues, which correlated strongly with poor patient survival. Mechanistically, their expression was suppressed in PC cell lines co-cultured with CAFs and inversely correlated with TGF-β1 and COL1A1 levels. Consistent with these findings, miR-4787-3p and miR-581 levels were markedly lower in PC patient tissues and blood samples compared to controls, with the lowest expression observed in high-fibrosis tissues. Both miRNAs demonstrated high sensitivity and specificity for distinguishing PC from non-cancerous controls and for identifying fibrosis within tumors.
conclusionThe downregulation of miR-4787-3p and miR-581 is a hallmark of pancreatic cancer, closely associated with tumor fibrosis and poor prognosis. These miRNAs represent promising circulating and tissue biomarker candidates for diagnosing PC and evaluating its fibrotic burden, suggesting potential utility for early detection and personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.